Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05887635
Other study ID # CLD-1021
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date September 2, 2023
Est. completion date October 2024

Study information

Verified date March 2024
Source Aqua Medical, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this clinical study is to test the hypothesis that RF vapor ablation of the duodenal mucosa will result in improvement in glycemic parameters, without complications (bleeding/ stricture / perforation). The main aims of the study are : 1. Evaluate the safety of the device and procedure based on the reported adverse events that occur. 2. Evaluate the effectiveness of the device and procedure by comparing change in HbA1c from baseline to 168 days post procedure. 3. Evaluate device tolerability based on pain scores reported by patients. The subject population for this study are adults (18-65 years of age) with type-2 diabetes mellitus. Study participation is 6 months for each patient. The study is comprised of 4 phases: Screening, Run-in, RF Vapor ablation procedure, and Post-vapor ablation follow-up (up to 168 days).


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 30
Est. completion date October 2024
Est. primary completion date August 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: 1. Men and non-pregnant women 18-65 years of age 2. Diagnosed with T2D for at least 3 years and less than or equal to 10 years 3. HbA1C of 7.5 - 10% (59-86 mmol/mol) 4. BMI = 24 and = 40 kg/m2 5. On a minimum of 1 stable oral anti-diabetic medications with no changes in medication in the previous 3 months prior to study entry Note: For subjects on sulfonylurea (SU) glucose-lowering drugs for diabetes, the only SUs permitted in the study will be glipizide or glimepiride, and their doses below half maximum labeled dosing will not be an exclusion for study entry. Subjects unwilling to reduce the dose of SU at the run-in period will be excluded. 6. Agrees to use an additional glucose-lowering treatment (e.g., liraglutide, other OAD with the exception of glyburide), if recommended by the study Investigator in case of persistent hyperglycemia. 7. Able to comply with study requirements and understand and sign the Informed Consent Form Exclusion Criteria: 1. Diagnosis of Type-1 Diabetes 2. History of diabetic ketoacidosis or hyperosmolar nonketotic coma. 3. Probable insulin production failure, defined as fasting C Peptide serum <1 ng/mL (333pmol/l). 4. Previous use of any types of insulin for >1 month (at any time, except for treatment of gestational diabetes). 5. Current use of injectable medications for diabetes (insulin, GLP-1RA). 6. Current use of glyburide, a sulfonylurea (SU) glucose-lowering drug for diabetes. 7. History of severe hypoglycemia (more than 1 severe hypoglycemic event, as defined by need for third-party assistance, in the last year). 8. Known autoimmune disease, including but not limited to celiac disease, duodenal Crohn disease or pre-existing symptoms of systemic lupus erythematosus, scleroderma or other systemic autoimmune connective tissue disorder. 9. Previous GI surgery that could limit treatment of the duodenum such as Billroth 2, Roux-en-Y gastric bypass, or other similar procedures or conditions. (Prior laparoscopic sleeve gastrectomy (LSG) will not be an exclusion) 10. History of chronic or acute pancreatitis. 11. History of diabetic gastroparesis. 12. Known active hepatitis or active liver disease. 13. Acute gastrointestinal illness in the previous 7 days. 14. Known history of severe irritable bowel syndrome, radiation enteritis or other inflammatory bowel disease, such as Crohn's disease. 15. Known history of a structural or functional disorder of the esophagus that may impede passage of the device through the gastrointestinal tract or increase risk of esophageal damage during an endoscopic procedure, including moderate-severe (Grade C or D) esophagitis, dysphagia due to achalasia or stricture/stenosis, esophageal varices, esophageal perforation, or any other disorder of the esophagus. 16. Upper gastrointestinal conditions such as active ulcers, polyps, varices, strictures, congenital or acquired duodenal telangiectasia 17. Current use of anticoagulation therapy (such as warfarin) that cannot be discontinued for 7 days before and 14 days after the procedure. 18. Current use of P2Y12 inhibitors (clopidogrel, prasugrel, ticagrelor) that cannot be discontinued for 14 days before and 14 days after the procedure. 19. Unable to discontinue non-steroidal anti-inflammatory drugs (NSAIDs) during treatment through 4 weeks following the procedure. Use of acetaminophen and low dose aspirin is allowed. 20. Use of systemic glucocorticoids (excluding topical or ophthalmic application or inhaled forms) for more than 10 consecutive days within 12 weeks prior to the baseline visit. 21. Use of drugs known to affect GI motility (e.g. Metoclopramide) 22. Use of weight loss medications such as Sibutramine (e.g. Meridia), Orlistat (e.g. Xenical), Phentermine or over-the-counter weight loss medications (prescription medication) 23. Currently taking, or unable to stop taking dietary supplements or herbal agents, including vitamin C or multivitamins containing vitamin C at >500 mg per day, multivitamins containing biotin (vitamin B7), and supplements for hair, skin, and nail growth. Multivitamins not containing biotin are permitted. 24. Significant cardiovascular disease, including known history of valvular disease, or myocardial infarction, heart failure, transient ischemic attack, or stroke within 6 months prior to the Screening Visit. 25. Mean of 3 separate blood pressure measurements >180 mmHg (systolic) or >100 mmHg (diastolic). 26. Estimated glomerular filtration rate (eGFR) = 60 ml/min/1.73m2 (estimated by MDRD). 27. Known immunocompromised status, including but not limited to individuals who have undergone organ transplantation, chemotherapy, or radiotherapy within the past 12 months, who have clinically significant leukopenia, who are positive for the human immunodeficiency virus (HIV) or whose immune status makes the participant a poor candidate for clinical trial participation in the opinion of the investigator. 28. Active illicit substance abuse or alcoholism (>2 drinks/day regularly) 29. Active malignancy within the last 5 years (excluding non-melanoma skin cancers) 30. Women breastfeeding 31. Participating in another ongoing clinical trial of an investigational drug or device. 32. Any other mental or physical condition which, in the opinion of the study investigator, makes the participant a poor candidate for clinical trial participation. 33. Critically ill or has a life expectancy <3 years 34. Use of heart pacemaker or other electronic device implants 35. General contraindications to deep or conscious sedation, general anesthesia, high risk as determined by anesthesiologist (e.g., ASA score 4 or higher), or contraindications to upper GI endoscopy.

Study Design


Intervention

Device:
RF Vapor Ablation
RF Vapor ablation of the duodenum

Locations

Country Name City State
Chile Clinica Colonial Santiago

Sponsors (1)

Lead Sponsor Collaborator
Aqua Medical, Inc.

Country where clinical trial is conducted

Chile, 

Outcome

Type Measure Description Time frame Safety issue
Primary Safety endpoint Number of subjects with reported device or procedure related SAEs or UADEs. 1 month
Primary Efficacy endpoint Change in HbA1c from baseline to 168 days post procedure 6 months
Primary Tolerability Endpoint: Descriptive statistics on Visual Analogue Scale(VAS) pain scores 7 days
Secondary Change in HbA1c at 84 and 168 days post procedure Change in HbA1c (from baseline) at 84 and 168 days post procedure will be analyzed 168 days
Secondary Change in HbA1c by visit over time Change in HbA1c by visit over time, comparing with baseline 168 days
Secondary Change in FPG from baseline to 84 and 168 days post procedure Change in FPG from baseline to 84 and 168 days post procedure 168 days
Secondary Change in FPG change by visit over time (168 days post procedure) Change in FPG change by visit over time (168 days post procedure) 168 days
Secondary Proportion of ablation-treated subjects with an HbA1c improvement from baseline at 168 days Proportion of ablation-treated subjects with an HbA1c improvement from baseline at 168 days 168 days
Secondary Changes in HOMA-IR by visit over time (168 days post procedure). Changes in HOMA-IR by visit over time (168 days post procedure) from baseline 168 days
Secondary Change in UACR from baseline to 24 weeks post procedure Change in UACR from baseline to 24 weeks post procedure 24 weeks
Secondary Change in ALT and AST from baseline to 24 weeks post procedure. Change in ALT and AST from baseline to 24 weeks post procedure. 24 weeks
See also
  Status Clinical Trial Phase
Completed NCT01267448 - Outpatient Discharge Therapy With Saxagliptin+MetforminXR vs GlipizideXL for Type 2 Diabetes With Severe Hyperglycemia Phase 4
Active, not recruiting NCT05330247 - Cut Down on Carbohydrate in the Dietary Therapy of Type 2 Diabetes - The Meal Box Study N/A
Terminated NCT02743598 - Liraglutide for HIV-associated Neurocognitive Disorder Phase 4
Terminated NCT02373865 - Risk of Nocturnal Hypoglycemia and Arrhythmias With Sitagliptin Versus Glimepiride in Patients With Type 2 Diabetes Phase 4
Completed NCT01741181 - Vitamin D Supplementation in Patients With Diabetes Mellitus Type 2 Phase 4
Completed NCT01305434 - Mulberry Leaf Extract and Blood Glucose Control in Diabetics Phase 1/Phase 2
Completed NCT01330121 - Bridging the Gap by Transitional Care N/A
Recruiting NCT00992797 - Diabetes Intervention Trial With Vitamin D in Subjects of Nordic and Sub-Indian Ethnicity Phase 2
Completed NCT01580904 - Impact of Pharmaceutical Care in Diabetics Patients N/A
Active, not recruiting NCT00728403 - Metabolic and Therapeutic Effects of American and Korean Red Ginseng in the Treatment of Type 2 Diabetes Phase 2
Completed NCT00763815 - GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Pioglitazone Phase 3
Active, not recruiting NCT00529815 - Continuous Glucose Monitoring in Patients With Type 2 Diabetes Phase 4
Completed NCT00517465 - A Multiple Ascending Dose Study of R1511 in Patients With Type 2 Diabetes Mellitus. Phase 1
Completed NCT00119041 - Diabetes Telemedicine Consultation: A Systems Improvement Intervention N/A
Withdrawn NCT00417716 - Use of Intravitreal Bevacizumab in Patients With Diffuse Diabetic Macular Edema Phase 3
Withdrawn NCT00600236 - HLA and it Relation With the Development of Proliferative Diabetic Retinopathy in Mexican Population Phase 3
Completed NCT03903965 - Comparison of Retinal Perfusion Between Diabetic and Non-diabetic Patients With OCT Angiography After Cataract Surgery.
Completed NCT02666924 - Cooking Classes for Chinese Canadian Patients Living With Diabetes N/A
Recruiting NCT02501850 - The Effect of the GLP-1 Receptor Agonists on Blood Levels of Lipoprotein (a) Phase 4
Completed NCT02318797 - Optimizing Behavioral Health Homes for Adults With Serious Mental Illness N/A